Expression and localization of serotonin receptors in human breast cancer

Anticancer Research

Volumn 33, Issue 2, 2013, Pages 363-370

  Kopparapu, Pradeep Kumar ^a   Tinzl, Martina ^b   Anagnostaki, Lola ^c   Persson, Jenny Liao ^a   Dizeyi, Nishtman ^b,c  

^a Division of Experimental Cancer Research   (Sweden)

^b Clinical Research Center   (Sweden)

^c LUND UNIVERSITY   (Sweden)

Author keywords

5 HTRs; Breast cancer; Invasive ductal carcinoma; Invasive lobular carcinoma; Malignant; Non malignant; Serotonin

Indexed keywords

ESTROGEN RECEPTOR ALPHA; PROGESTERONE; SEROTONIN 1A RECEPTOR; SEROTONIN 1B RECEPTOR; SEROTONIN 2B RECEPTOR; SEROTONIN 4 RECEPTOR;

ADULT; AGED; ARTICLE; BREAST CANCER; CANCER CELL; CYTOPLASM; DIAGNOSTIC VALUE; HUMAN; IMMUNOHISTOCHEMISTRY; MAJOR CLINICAL STUDY; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN LOCALIZATION; TISSUE MICROARRAY;

BREAST NEOPLASMS; CELL MEMBRANE; CELL NUCLEUS; FEMALE; HUMANS; IMMUNOHISTOCHEMISTRY; RECEPTORS, SEROTONIN; TISSUE ARRAY ANALYSIS; TUMOR MARKERS, BIOLOGICAL;

EID: 84875893256     PISSN: 02507005     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (34)

1. Vollenweider-Zerargui L, Barrelet L, Wong Y, Lemarchand-Beraud T and Gomez F: The predictive value of estrogen and progesterone receptors' concentrations on the clinical behavior of breast cancer in women. Clinical correlation on 547 patients. Cancer 57: 1171-1180, 1986.
2. Geisler S, Lonning PE, Aas T, Johnsen H, Fluge O, Haugen DF, Lillehaug JR, Akslen LA and Borresen-Dale AL: Influence of TP53 gene alterations and c-erbB-2 expression on the response to treatment with doxorubicin in locally advanced breast cancer. Cancer Res 61: 2505-2512, 2001.
3. Albert JM, Gonzalez-Angulo AM, Guray M, Sahin A, Strom EA, Tereffe W, Woodward WA, Tucker SL, Hunt KK, Hortobagyi GN and Buchholz TA: Estrogen/progesterone receptor negativity and HER2 positivity predict locoregional recurrence in patients with T1a, bN0 breast cancer. Int J Radiat Oncol Biol Phys 77: 1296-1302, 2010.
4. Borresen AL, Andersen TI, Eyfjord JE, Cornelis RS, Thorlacius S, Borg A, Johansson U, Theillet C, Scherneck S, Hartman S et al: TP53 mutations and breast cancer prognosis: particularly poor survival rates for cases with mutations in the zinc-binding domains. Genes Chromosomes Cancer 14: 71-75, 1995.
5. Dizeyi N, Bjartell A, Nilsson E, Hansson J, Gadaleanu V, Cross N and Abrahamsson PA: Expression of serotonin receptors and role of serotonin in human prostate cancer tissue and cell lines. Prostate 59: 328-336, 2004.
6. Dizeyi N, Bjartell A, Hedlund P, Tasken KA, Gadaleanu V and Abrahamsson PA: Expression of serotonin receptors 2B and 4 in human prostate cancer tissue and effects of their antagonists on prostate cancer cell lines. Eur Urol 47: 895-900, 2005.
7. Henriksen R, Dizeyi N and Abrahamsson PA: Expression of serotonin receptors 5-HT1A, 5-HT1B, 5-HT2B and 5-HT4 in ovary and in ovarian tumours. Anticancer Res 32: 1361-1366, 2012.
8. Hoyer D, Clarke DE, Fozard JR, Hartig PR, Martin GR, Mylecharane EJ, Saxena PR and Humphrey PP: International Union of Pharmacology classification of receptors for 5-hydroxytryptamine (Serotonin). Pharmacol Rev 46: 157-203, 1994.
9. Pai VP, Marshall AM, Hernandez LL, Buckley AR and Horseman ND: Altered serotonin physiology in human breast cancers favors paradoxical growth and cell survival. Breast Cancer Res 11: R81, 2009.
10. Rinaldi A, Chiaravalli AM, Mian M, Zucca E, Tibiletti MG, Capella C and Bertoni F: Serotonin receptor 3A expression in normal and neoplastic B cells. Pathobiology 77: 129-135, 2010.
11. Soll C, Jang JH, Riener MO, Moritz W, Wild PJ, Graf R and Clavien PA: Serotonin promotes tumor growth in human hepatocellular cancer. Hepatology 51: 1244-1254, 2010.
12. Soll C, Riener MO, Oberkofler CE, Hellerbrand C, Wild PJ, Deoliveira ML and Clavien PA: Expression of serotonin receptors in human hepatocellular cancer. Clin Cancer Res 18: 5902-5910, 2012.
13. Sonier B, Arseneault M, Lavigne C, Ouellette RJ and Vaillancourt C: The 5-HT2A serotoninergic receptor is expressed in the MCF-7 human breast cancer cell line and reveals a mitogenic effect of serotonin. Biochem Biophys Res Commun 343: 1053-1059, 2006.
14. Siddiqui EJ, Shabbir M, Mikhailidis DP, Thompson CS and Mumtaz FH: The role of serotonin (5-hydroxytryptamine1A and 1B) receptors in prostate cancer cell proliferation. J Urol 176: 1648-1653, 2006.
15. Oufkir T and Vaillancourt C: Phosphorylation of JAK2 by serotonin 5-HT (2A) receptor activates both STAT3 and ERK1/2 pathways and increases growth of JEG-3 human placental choriocarcinoma cell. Placenta 32: 1033-1040, 2011.
16. Takai D, Yagi Y, Wakazono K, Ohishi N, Morita Y, Sugimura T and Ushijima T: Silencing of HTR1B and reduced expression of EDN1 in human lung cancers, revealed by methylation-sensitive representational difference analysis. Oncogene 20: 7505-7513, 2001.
17. Dizeyi N, Hedlund P, Bjartell A, Tinzl M, Austild-Tasken K and Abrahamsson PA: Serotonin activates MAP kinase and PI3K/Akt signaling pathways in prostate cancer cell lines. Urol Oncol 29: 436-445, 2011.
18. Drozdov I, Kidd M, Gustafsson BI, Svejda B, Joseph R, Pfragner R and Modlin IM: Autoregulatory effects of serotonin on proliferation and signaling pathways in lung and small intestine neuroendocrine tumor cell lines. Cancer 115: 4934-4945, 2009.
19. Nebigil CG, Launay JM, Hickel P, Tournois C and Maroteaux L: 5-hydroxytryptamine 2B receptor regulates cell-cycle progression: cross-talk with tyrosine kinase pathways. Proc Natl Acad Sci USA 97: 2591-2596, 2000.
20. Lefebvre H, Cartier D, Duparc C, Lihrmann I, Contesse V, Delarue C, Godin M, Fischmeister R, Vaudry H and Kuhn JM: Characterization of serotonin(4) receptors in adrenocortical aldosterone-producing adenomas: in vivo and in vitro studies. J Clin Endocrinol Metab 87: 1211-1216, 2002.
21. Contesse V, Reznik Y, Duparc C, Perraudin V, Vaudry H, Kuhn JM and Lefebvre H: Effects of serotonin and vasopressin on cortisol production from an adrenocortical tumor causing subclinical Cushing's syndrome. Endocr Res 28: 787-791, 2002.
22. Pai VP and Horseman ND: Multiple cellular responses to serotonin contribute to epithelial homeostasis. PLoS One 6: e17028, 2011.
23. Rybaczyk LA, Bashaw MJ, Pathak DR, Moody SM, Gilders RM and Holzschu DL: An overlooked connection: serotonergic mediation of estrogen-related physiology and pathology. BMC Womens Health 5: 12, 2005.
24. Hernandez LL, Gregerson KA and Horseman ND: Mammary gland serotonin regulates parathyroid hormone-related protein and other bone-related signals. Am J Physiol Endocrinol Metab 302: E1009-1015, 2012.
25. Paik S, Bryant J, Park C, Fisher B, Tan-Chiu E, Hyams D, Fisher ER, Lippman ME, Wickerham DL and Wolmark N: erbB-2 and response to doxorubicin in patients with axillary lymph nodepositive, hormone receptor-negative breast cancer. J Natl Cancer Inst 90: 1361-1370, 1998.
26. Brouland JP, Manivet P, Brocheriou-Spelle I, Wassef M, Le Bodic MF, Lavergne A and Launay JM: Histological, immunohistochemical, ultrastructural and biochemical study of human gastric composite tumor: expression of the serotonin-2B receptor by the neuroendocrine component. Endocr Pathol 12: 77-86, 2001.
27. Launay JM, Birraux G, Bondoux D, Callebert J, Choi DS, Loric S and Maroteaux L: Ras involvement in signal transduction by the serotonin 5-HT2B receptor. J Biol Chem 271: 3141-3147, 1996.
28. Zamani A and Qu Z: Serotonin activates angiogenic phosphorylation signaling in human endothelial cells. FEBS Lett 586: 2360-2365, 2012.
29. Domingues I, Rino J, Demmers JA, de Lanerolle P and Santos SC: VEGFR2 translocates to the nucleus to regulate its own transcription. PLoS One 6: e25668, 2011.
30. Kampen KR: The mechanisms that regulate the localization and overexpression of VEGF receptor-2 are promising therapeutic targets in cancer biology. Anticancer Drugs 23: 347-354, 2012.
31. Ferguson SS: Evolving concepts in G protein-coupled receptor endocytosis: the role in receptor desensitization and signaling. Pharmacol Rev 53: 1-24, 2001.
32. Drake MT, Shenoy SK and Lefkowitz RJ: Trafficking of G protein-coupled receptors. Circ Res 99: 570-582, 2006.
33. Kovacs JJ, Hara MR, Davenport CL, Kim J and Lefkowitz RJ: Arrestin development: emerging roles for beta-arrestins in developmental signaling pathways. Dev Cell 17: 443-458, 2009.
34. Papoucheva E, Dumuis A, Sebben M, Richter DW and Ponimaskin EG: The 5-hydroxytryptamine(1A) receptor is stably palmitoylated, and acylation is critical for communication of receptor with Gi protein. J Biol Chem 279: 3280-3291, 2004.